Authors
Claudio Conforti, Luca Ambrosio, Marina Agozzino, Roberta Giuffrida, Fabrizio Guarneri, Nicola DI Meo, Caterina Dianzani, Caterina Longo, Giovanni Pellacani, Iris Zalaudek
Published in
Italian journal of dermatology and venereology. Volume 161. Issue 5. Pages 419-424.
Abstract
Photodynamic therapy (PDT) is a widely used non-invasive treatment for actinic keratoses (AK) and selected non-melanoma skin cancers (NMSC). Conventional PDT (c-PDT) and daylight PDT (dl-PDT) have shown comparable efficacy, with differences mainly related to tolerability. This study aimed to compare clinical outcomes, pain, and Quality of Life in a real-life setting.
We conducted a retrospective observational study including 90 patients treated with c-PDT or dl-PDT at the Skin Cancer Unit of Trieste, Italy, between November 2019 and January 2020. Lesions included AK, superficial basal cell carcinoma, Bowen disease, and superficial squamous cell carcinoma. Clinical efficacy was assessed by evaluating changes in lesion diameter, including absolute reduction (delta). Pain was measured using the Visual Analog Scale (VAS), and Quality of Life using the Dermatology Life Quality Index (DLQI), at baseline, immediately after treatment, and during follow-up.
Both c-PDT and dl-PDT resulted in a significant reduction in lesion diameter compared to baseline. When accounting for baseline differences using delta analysis, both treatments demonstrated effective lesion reduction, with differences in treatment dynamics. Pain significantly increased immediately after treatment in both groups but was consistently lower in the dl-PDT group and returned to baseline levels more rapidly. DLQI improved over time in both groups, reflecting an overall benefit in patient-reported outcomes.
In this real-life cohort, both c-PDT and dl-PDT were effective in reducing lesion size. While direct comparison of efficacy is limited by baseline differences, dl-PDT was associated with a more favorable tolerability profile, particularly in terms of pain. These findings support the use of dl-PDT as a well-tolerated therapeutic option in appropriately selected patients.
PMID:
43043300
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 9
- Comments 0